A detailed history of Cormorant Asset Management, LP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,170,870 shares of BCAB stock, worth $1.6 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
1,170,870
Previous 1,181,115 0.87%
Holding current value
$1.6 Million
Previous $2.91 Million 38.62%
% of portfolio
0.23%
Previous 0.17%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.88 - $3.46 $19,260 - $35,447
-10,245 Reduced 0.87%
1,170,870 $4.03 Million
Q1 2023

May 15, 2023

SELL
$2.3 - $8.25 $5.75 Million - $20.6 Million
-2,499,250 Reduced 67.91%
1,181,115 $3.17 Million
Q4 2022

Feb 14, 2023

BUY
$7.63 - $11.01 $11.4 Million - $16.5 Million
1,499,250 Added 68.74%
3,680,365 $30.4 Million
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $420,126 - $1.7 Million
142,900 Added 7.01%
2,181,115 $16.8 Million
Q1 2022

May 16, 2022

BUY
$4.38 - $18.78 $1.56 Million - $6.71 Million
357,100 Added 21.24%
2,038,215 $10.2 Million
Q4 2021

Feb 14, 2022

SELL
$19.0 - $30.95 $2.55 Million - $4.16 Million
-134,431 Reduced 7.4%
1,681,115 $33 Million
Q3 2021

Nov 15, 2021

SELL
$29.44 - $43.74 $4.01 Million - $5.96 Million
-136,172 Reduced 6.98%
1,815,546 $53.5 Million
Q2 2021

Aug 16, 2021

SELL
$38.07 - $56.17 $9.15 Million - $13.5 Million
-240,342 Reduced 10.96%
1,951,718 $82.7 Million
Q1 2021

May 17, 2021

SELL
$32.41 - $70.91 $3.24 Million - $7.09 Million
-100,000 Reduced 4.36%
2,192,060 $110 Million
Q4 2020

Feb 16, 2021

BUY
$31.02 - $35.16 $71.1 Million - $80.6 Million
2,292,060 New
2,292,060 $75.4 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $49.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.